💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vancomycin

CHEMBL262777 Phase 4 Zugelassen Small molecule
Half-Life
4-6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
1449.2 g/mol
LogP
-2.6
Phase
4

This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

Molekularmasse

1449,2500 g/mol

LogP

-2,60

TPSA

530,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Malaria Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Arzneimittelklassen

J — J - Antiinfectives for Systemic Use

Wirkmechanismus

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Pharmacokinetics (PK)

Half-Life 4-6 hours

Pharmacodynamics (PD)

Mechanismus

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C66H75Cl2N9O24

                    

                    
                    

                        
HBD / HBA

                        
19 / 26

                    

                    
                    

                        
Rotierbare Bindungen

                        
13

                    

                    
                    
                    

                        
Schwere Atome

                        
101

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Vancomycin: Half-life: 4-6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Vancomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL262777.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 14969.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.